Paladin makes hostile bid for Afexa

Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences in a deal that values the company at $56.7 million. Investors in Afexa, which makes the flu drug COLD-FX, are being offered 55 cents a share for the 85% of the company Paladin doesn't already own. "Our offer provides an opportunity for Afexa shareholders to receive an immediate and attractive cash premium for their investment at a time when the outlook for Afexa is uncertain," Paladin president and CEO Jonathan Ross Goodman said in a statement. Afexa's board has rejected the offer as inadequate. Report 

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.